PureTech appoints George Farmer as Chief Financial Officer
PureTech Health, a clinical-stage biotherapeutics company focused on highly differentiated medicines for devastating diseases, has appointed Dr George Farmer as its Chief Financial Officer.
As a key member of PureTech’s senior leadership team, Farmer will be responsible for all aspects of the company’s finances, including capital markets strategy and execution, strategic and financial planning, and financial reporting.
Farmer joins PureTech from BMO Capital Markets, where he completed a 15-year career as a senior biotechnology equity analyst providing in-depth sector research for institutional investor clients. Prior to this role, Farmer served as Chief Executive Officer of Cortice Biosciences, a privately held biotechnology company focused on the clinical development of therapies for brain malignancies and neurodegenerative diseases. He also served as Vice President of Corporate Development at Synta Pharmaceuticals, a publicly traded company developing cancer therapeutics. Farmer was a postdoctoral fellow at Sloan Kettering Cancer Center and University of California San Francisco after receiving his PhD in Biological Sciences from Columbia University and a BA from Dartmouth College.
Farmer himself said: “PureTech has built a leadership position in the science of the brain-immune-gut axis, which has led to the discovery and development of novel medicines. I am particularly intrigued by the potential of LYT-100 for treating multiple fibrotic diseases and LYT-200 as a potential new cancer immunotherapeutic.
“Just as impressive is the track record of management, which has developed a deep therapeutic pipeline both internally and through the company’s Founded Entities. I am very excited to become a member of the PureTech team.”